CTRI/2018/09/015586已完成未知
A Prospective, Randomized, Double Blinded, Placebo Controlled, ParallelGroup, Proof of Concept Study to Assess the Effect of Nutraceutical Formulations in Pre-diabetic Subjects
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female aged between 25-65 years
- •2. Subjects with BMI of >=23 to <= 35 kg/m2
- •3. Subject with a HbA1c levels of 5.7-6.4% (39-46 mmol/mol) as per the
- •American Diabetes Association at the time of screening
- •4. Subjects with liver (alanine transaminase, aspartate transaminase, total
- •and direct bilirubin, gamma glutamyl transferase, alkaline phosphatase,
- •total proteins, and albumin) and renal (serum creatinine and blood urea
- •nitrogen) function parameters within normal laboratory reference range at
- •5. Females of childbearing potential must have a negative serum pregnancy
- •test (human chorionic gonadotropin, beta subunit [β-hCG]) at screening
- •6. Males and females of childbearing potential willing to practice
- •appropriate birth control during the entire duration of the study.
- •Appropriate birth control is defined in the study as any medically
- •recommended method (or combination of methods) except oral birth
- •control pills as per standard of care
- •7. Subject is willing to provide written informed consent
- •8. Subject is willing, able and likely to comply with all study procedures and
- •restrictions
排除标准
- •1.Subject with a history of diabetes mellitus (type 1/ type 2/ gestational/secondary etc.)
- •2.Subject has used any anti-diabetic medication for blood sugar control or other medical conditions (e.g. metformin in polycystic ovarian disease)any time during the past 6 months
- •3. Subject is taking medications known to interfere with glucose metabolism e.g. systemic corticosteroids, protease inhibitors, antidepressants, or antipsychotics) or any other medications in the opinion of investigator that
- •may interfere with study outcomes
- •4. Subjects with a history of use of other herbal or nutritional supplements that modify glucose absorption and/or metabolism in the past 6 months
- •5. Subjects with a history of use of weight loss drugs (orlistat, lorcaserin, phentermine-topiramate, naltrexone-bupropion etc) in the past 6 months.
- •6. Subject has had a weight loss or gain of greater >=5% of body weight in the 6 months prior to screening.
- •7. Hemoglobin levels of <11 g/dl
- •8. Subject with a history of clotting/bleeding disorders such as hemophilia,Von Willebrand disease, disseminated intravascular coagulation, vitamin K deficiency or subjects who required blood transfusion in the past 3 months.
- •9. Subject with history of significant renal, hepatic, cardiovascular, hematologic, metabolic, ophthalmologic, respiratory, gastrointestinal,
- •cerebrovascular, neurologic, endocrine dysfunction, malignancy, or any other significant medical illness or disorder which, in the judgment of the investigator could interfere with the study or require treatment(s) which might interfere with study or which may pose risk to the patient
- •10. History of drug abuse or alcohol consumption ( >20 g/day in women and >30 g/day in men) and smoking ( >5 pack-years cigarettes)
- •11. History of participation in other interventional studies within last 60 days
- •12. History of blood donation within last 30 days
- •13. Subjects with inadequate peripheral venous access, such that intravenous catheterization for serial blood collection is difficult.
- •14. Subject is pregnant or breast-feeding at the time of screening, or planning to be pregnant during the study
- •15. Subject has known allergies to the herbal products or allergy to any of the components of the study product
- •16. Any other condition, that in the investigatorâ??s judgment, might interfere
- •with study objectives
研究者
相似试验
已完成
不适用
Study of nutraceutical formulation in healthy subjects with mild damage of lung function due to long term exposure to polluted environment.CTRI/2018/10/016195Amway India Enterprises Pvt Ltd56
进行中（未招募）
1 期
A Randomised, Prospective, Double Blinded, Placebo Controlled Trial to Determine the Efficacy of Continuous Infusion Ankle Block Compared to Standard Single Bolus Block in the Management of Postoperative Pain Following Foot and Ankle Surgery - Ankle Block StudyAny Orthopaedic condition which would require ankle or hind foot surgery under Mr. James Calder at North Hampshire Hospital, Basingstoke.EUCTR2005-006172-35-GBorth Hampshire Hospital NHS Trust56
已完成
不适用
A Randomised, Prospective, Double Blinded, Placebo Controlled Trial to Determine the Efficacy of Continuous Infusion Ankle Block Compared to Standard Single Bolus Block in the Management of Postoperative Pain Following Foot and Ankle SurgeryISRCTN57941461Record Provided by the NHSTCT Register - 2006 Update - Department of Health56
进行中（未招募）
1 期
Planned, randomized trial where placebo is used and the drug. No one would know which subject has the drug and which one has placebo. Trial is phase 3 study and will study how safe and effective the drug is with subjects who have Advanced or Metastatic Gastric Cancer (GC)Advanced or Metastatic Gastric CancerEUCTR2016-003984-20-PLSK BioPartners, Inc459
进行中（未招募）
1 期
Planned, randomized trial where placebo is used and the drug. No one would know which subject has the drug and which one has placebo. Trial is phase 3 study and will study how safe and effective the drug is with subjects who have Advanced or Metastatic Gastric Cancer (GC)Advanced or Metastatic Gastric CancerEUCTR2016-003984-20-DEElevar Therapeutics, Inc459